Gut microbes and immunotherapy for non-small cell lung cancer: a systematic review
Emerging evidence underscores gut microbiota’s role in modulating lung cancer immunotherapy outcomes, though specific impacts on immune checkpoint inhibitors (ICIs) and associated adverse events (AEs) require further clarity. This review synthesizes findings from 15 studies examining gut microbiota-...
Saved in:
| Main Authors: | Yali Jin, Zhiqian Jie, Xianming Fan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1518474/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
by: Jiexi Yan, et al.
Published: (2024-11-01) -
HCC and Immunotherapy: The Potential Predictive Role of Gut Microbiota and Future Therapeutic Strategies
by: Carmelo Laface, et al.
Published: (2025-02-01) -
The metabolic dialogue between intratumoural microbes and cancer: implications for immunotherapy
by: Yingheng Situ, et al.
Published: (2025-05-01) -
Immunotherapy for Extensive-stage Small Cell Lung Cancer:
Research Progress and Future Perspectives
by: Yuling ZHONG, et al.
Published: (2024-11-01) -
Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer
by: Xinyue YANG, et al.
Published: (2025-05-01)